Format

Send to

Choose Destination
Front Immunol. 2018 Aug 30;9:1962. doi: 10.3389/fimmu.2018.01962. eCollection 2018.

TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features.

Simon S1,2, Wu Z3, Cruard J1,2, Vignard V1,2,4, Fortun A1,2, Khammari A1,2,5, Dreno B1,2,5, Lang F1,2, Rulli SJ3, Labarriere N1,2,4.

Author information

1
CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
2
LabEx IGO "Immunotherapy, Graft, Oncology," Nantes, France.
3
Qiagen Sciences, Frederick, MD, United States.
4
Centre Hospitalier Universitaire Nantes, Nantes, France.
5
Department of Dermato-Cancerology of Nantes Hospital, Nantes, France.

Abstract

Among Immunotherapeutic approaches for cancer treatment, the adoptive transfer of antigen specific T cells is still a relevant approach, that could have higher efficacy when further combined with immune check-point blockade. A high number of adoptive transfer trials have been performed in metastatic melanoma, due to its high immunogenic potential, either with polyclonal TIL or antigen-specific polyclonal populations. In this setting, the extensive characterization of T cell functions and receptor diversity of infused polyclonal T cells is required, notably for monitoring purposes. We developed a clinical grade procedure for the selection and amplification of polyclonal CD8 T cells, specific for two shared and widely expressed melanoma antigens: Melan-A and MELOE-1. This procedure is currently used in a clinical trial for HLA-A2 metastatic melanoma patients. In this study, we characterized the T-cell diversity (T-cell repertoire) of such T cell populations using a new RNAseq strategy. We first assessed the added-value of TCR receptor sequencing, in terms of sensitivity and specificity, by direct comparison with cytometry analysis of the T cell populations labeled with anti-Vß-specific antibodies. Results from these analyzes also confirmed specific features already reported for Melan-A and MELOE-1 specific T cell repertoires in terms of V-alpha recurrence usage, on a very high number of T cell clonotypes. Furthermore, these analyses also revealed undescribed features, such as the recurrence of a specific motif in the CDR3α region for MELOE-1 specific T cell repertoire. Finally, the analysis of a large number of T cell clonotypes originating from various patients revealed the existence of public CDR3α and ß clonotypes for Melan-A and MELOE-1 specific T cells. In conclusion, this method of high throughput TCR sequencing is a reliable and powerful approach to deeply characterize polyclonal T cell repertoires, and to reveal specific features of a given TCR repertoire, that would be useful for immune follow-up of cancer patients treated by immunotherapeutic approaches.

KEYWORDS:

MELOE-1; Melan-A; TCR sequencing; immunotherapy; melanoma

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center